Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study-

PLoS ONE

Volumn 13, Issue 3, 2018, Pages

  Ebina, Kosuke ^a   Hashimoto, Motomu ^b   Yamamoto, Wataru ^b,c   Ohnishi, Akira ^d   Kabata, Daijiro ^e   Hirano, Toru ^a   Hara, Ryota ^f   Katayama, Masaki ^g   Yoshida, Shuzo ^h   Nagai, Koji ^h   Son, Yonsu ⁱ   Amuro, Hideki ⁱ   Akashi, Kengo ^d   Fujimura, Takanori ^f   Hirao, Makoto ^a   Yamamoto, Keiichi ^e   Shintani, Ayumi ^e   Kumanogoh, Atsushi ^a   Yoshikawa, Hideki ^a  

^a OSAKA UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c Kurashiki Municipal Hospital   (Japan)

^d KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f NARA MEDICAL UNIVERSITY   (Japan)

^g OSAKA RED CROSS HOSPITAL   (Japan)

^h OSAKA MEDICAL COLLEGE   (Japan)

ⁱ KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; PREDNISOLONE; TOCILIZUMAB; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; DAS28; DISEASE ACTIVITY SCORE; DISEASE DURATION; DRUG EFFICACY; DRUG RESPONSE; DRUG RETENTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEMATOLOGIC DISEASE; HUMAN; INFECTION; KIDNEY DISEASE; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; PATIENT PREFERENCE; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SKIN MANIFESTATION; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; AGED; CLINICAL TRIAL; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; PROPORTIONAL HAZARDS MODEL; REMISSION; TREATMENT OUTCOME;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 85044193387     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0194130     Document Type: Article

References (35)

1. Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum. 2009; 61(5):560–8. Epub 2009/05/01. https://doi.org/10.1002/art.24463 PMID: 19405000.
2. Favalli EG, Pregnolato F, Biggioggero M, Becciolini A, Penatti AE, Marchesoni A, et al. Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry. Arthritis Care Res (Hoboken). 2016; 68(4):432–9. Epub 2015/11/12. https://doi.org/10.1002/acr.22788 PMID: 26556048.
3. Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 2010; 62(1):22–32. Epub 2009/12/30. https://doi.org/10.1002/art.27227 PMID: 20039405.
4. Neovius M, Arkema EV, Olsson H, Eriksson JK, Kristensen LE, Simard JF, et al. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab. Ann Rheum Dis. 2015; 74(2):354–60. Epub 2013/11/29. https://doi.org/10.1136/annrheumdis-2013-204128 [pii]. PMID: 24285495; PubMed Central PMCID: PMC4316855.
5. Souto A, Maneiro JR, Gomez-Reino JJ. Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases. Rheumatology (Oxford). 2016; 55(3):523–34. Epub 2015/10/23. https://doi.org/10.1093/rheumatology/kev374 kev374 [pii]. PMID: 26490106.
6. Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014; 73(3):492–509. Epub 2013/10/29. https://doi.org/10.1136/annrheumdis-2013-204573 [pii]. PMID: 24161836; PubMed Central PMCID: PMC3933074.
7. Wolfe F, Michaud K, Dewitt EM. Why results of clinical trials and observational studies of antitumour necrosis factor (anti-TNF) therapy differ: methodological and interpretive issues. Ann Rheum Dis. 2004; 63 Suppl 2:ii13–ii7. Epub 2004/10/14. doi: 63/suppl_2/ii13 [pii] https://doi.org/10.1136/ard.2004.028530PMID: 15479864; PubMed Central PMCID: PMC1766767.
8. Favalli EG, Biggioggero M, Marchesoni A, Meroni PL. Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies. Rheumatology (Oxford). 2014; 53 (9):1664–8. Epub 2014/04/15. https://doi.org/10.1093/rheumatology/keu158 keu158 [pii]. PMID: 24729445.
9. Gabay C, Riek M, Scherer A, Finckh A. Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry. Rheumatology (Oxford). 2015; 54(9):1664–72. Epub 2015/04/30. https://doi.org/10.1093/rheumatology/kev019 kev019 [pii]. PMID: 25922549.
10. Jorgensen TS, Kristensen LE, Christensen R, Bliddal H, Lorenzen T, Hansen MS, et al. Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry. Rheumatology (Oxford). 2015; 54 (12):2156–65. Epub 2015/07/16. https://doi.org/10.1093/rheumatology/kev216 kev216 [pii]. PMID: 26175471.
11. Hjardem E, Hetland ML, Ostergaard M, Krogh NS, Kvien TK. Prescription practice of biological drugs in rheumatoid arthritis during the first 3 years of post-marketing use in Denmark and Norway: criteria are becoming less stringent. Ann Rheum Dis. 2005; 64(8):1220–3. Epub 2005/01/11. doi: ard.2004.031252 [pii] https://doi.org/10.1136/ard.2004.031252 PMID: 15640272; PubMed Central PMCID: PMC1755604.
12. Hyrich KL, Watson KD, Lunt M, Symmons DP. Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008. Rheumatology (Oxford). 2011; 50(1):117–23. Epub 2010/07/31. https://doi.org/10.1093/rheumatology/keq209 keq209 [pii]. PMID: 20671021; PubMed Central PMCID: PMC2999956.
13. Simard JF, Arkema EV, Sundstrom A, Geborek P, Saxne T, Baecklund E, et al. Ten years with biologics: to whom do data on effectiveness and safety apply? Rheumatology (Oxford). 2011; 50(1):204–13. Epub 2010/11/19. https://doi.org/10.1093/rheumatology/keq326 keq326 [pii]. PMID: 21084326.
14. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988; 31(3):315–24. Epub 1988/03/01. PMID: 3358796.
15. Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, et al. Safety and effectiveness of 6 months’ etanercept monotherapy and combination therapy in Japanese patients with rheumatoid arthritis: effect of concomitant disease-modifying antirheumatic drugs. J Rheumatol. 2013; 40(10):1658–68. Epub 2013/08/03. https://doi.org/10.3899/jrheum.120490 [pii]. PMID: 23908446.
16. Koyama Y, Shiraishi H, Ohta T, Uchino A. Etanercept in combination with conventional disease-modifying antirheumatic drugs (DMARDs) in the treatment of rheumatoid arthritis patients intolerant to methotrexate. Mod Rheumatol. 2012; 22(1):100–8. Epub 2011/06/28. https://doi.org/10.1007/s10165-011-0478-8 PMID: 21706263.
17. Yoshikawa A, Yoshida S, Kimura Y, Tokai N, Fujiki Y, Kotani T, et al. Add-on iguratimod as a therapeutic strategy to achieve remission in patients with rheumatoid arthritis inadequately responding to biological DMARDs: A retrospective study. Mod Rheumatol. 2017:1–8. Epub 2017/06/24. https://doi.org/10.1080/14397595.2017.1336865 PMID: 28644744.
18. Soliman MM, Ashcroft DM, Watson KD, Lunt M, Symmons DP, Hyrich KL. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2011; 70(4):583–9. Epub 2011/02/19. https://doi.org/10.1136/ard.2010.139774 [pii]. PMID: 21330639; PubMed Central PMCID: PMC3048625.
19. Kaneshiro S, Ebina K, Hirao M, Tsuboi H, Nishikawa M, Nampei A, et al. The efficacy and safety of additional administration of tacrolimus in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab. Mod Rheumatol. 2017; 27(1):42–9. Epub 2016/05/18. https://doi.org/10.1080/14397595.2016.1181315 PMID: 27181115.
20. Takeuchi T, Ishida K, Shiraki K, Yoshiyasu T. Safety and effectiveness of tacrolimus add-on therapy for rheumatoid arthritis patients without an adequate response to biological disease-modifying anti-rheumatic drugs (DMARDs): Post-marketing surveillance in Japan. Mod Rheumatol. 2017:1–10. Epub 2017/06/27. https://doi.org/10.1080/14397595.2017.1332471 PMID: 28649878.
21. Greenberg JD, Reed G, Decktor D, Harrold L, Furst D, Gibofsky A, et al. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis. 2012; 71(7):1134–42. Epub 2012/ 02/02. https://doi.org/10.1136/annrheumdis-2011-150573 [pii]. PMID: 22294625.
22. Kanda Y. Investigation of the freely available easy-to-use software’EZR’ for medical statistics. Bone Marrow Transplant. 2013; 48(3):452–8. Epub 2012/12/05. https://doi.org/10.1038/bmt.2012.244 [pii]. PMID: 23208313; PubMed Central PMCID: PMC3590441.
23. Hishitani Y, Ogata A, Shima Y, Hirano T, Ebina K, Kunugiza Y, et al. Retention of tocilizumab and antitumour necrosis factor drugs in the treatment of rheumatoid arthritis. Scand J Rheumatol. 2013; 42 (4):253–9. Epub 2013/03/09. https://doi.org/10.3109/03009742.2012.762037 PMID: 23470089.
24. Kubo S, Nakayamada S, Nakano K, Hirata S, Fukuyo S, Miyagawa I, et al. Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching. Ann Rheum Dis. 2016; 75(7):1321–7. Epub 2015/08/08. https://doi.org/10.1136/annrheumdis-2015-207784[pii]. PMID: 26245754.
25. Leffers HC, Ostergaard M, Glintborg B, Krogh NS, Foged H, Tarp U, et al. Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry. Ann Rheum Dis. 2011; 70(7):1216–22. Epub 2011/05/10. https://doi.org/10.1136/ard.2010.140129 [pii]. PMID: 21551512.
26. Detert J, Bastian H, Listing J, Weiss A, Wassenberg S, Liebhaber A, et al. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Ann Rheum Dis. 2013; 72(6):844–50. Epub 2012/06/29. https://doi.org/10.1136/annrheumdis-2012-201612 [pii]. PMID: 22739990.
27. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005; 52(11):3381–90. Epub 2005/11/01. https://doi.org/10.1002/art.21405 PMID: 16258899.
28. Hirata S, Saito K, Kubo S, Fukuyo S, Mizuno Y, Iwata S, et al. Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational study. Arthritis Res Ther. 2013; 15(5):R135. Epub 2013/11/ 30. https://doi.org/10.1186/ar4315 [pii]. PMID: 24286472; PubMed Central PMCID: PMC3978613.
29. Kavanaugh A, Fleischmann RM, Emery P, Kupper H, Redden L, Guerette B, et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis. 2013; 72(1):64–71. Epub 2012/05/09. https://doi. org/10.1136/annrheumdis-2011-201247 [pii]. PMID: 22562973; PubMed Central PMCID: PMC3551224.
30. Smolen JS, Emery P, Ferraccioli GF, Samborski W, Berenbaum F, Davies OR, et al. Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial. Ann Rheum Dis. 2015; 74(5):843–50. Epub 2014/01/17. https://doi.org/10.1136/annrheumdis-2013-204632 [pii]. PMID: 24431394; PubMed Central PMCID: PMC4392224.
31. Smolen JS, Nash P, Durez P, Hall S, Ilivanova E, Irazoque-Palazuelos F, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet. 2013; 381(9870):918–29. Epub 2013/01/22. https://doi.org/10.1016/S0140-6736(12)61811-X [pii]. PMID: 23332236.
32. Tanaka Y, Hirata S, Saleem B, Emery P. Discontinuation of biologics in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2013; 31(4 Suppl 78):S22–7. Epub 2013/11/06. doi: 7386 [pii]. PMID: 24129132.
33. Tanaka Y, Takeuchi T, Mimori T, Saito K, Nawata M, Kameda H, et al. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis. 2010; 69(7):1286–91. Epub 2010/04/03. https://doi.org/10.1136/ard.2009.121491 [pii]. PMID: 20360136; PubMed Central PMCID: PMC3015067.
34. Forsblad-d’Elia H, Bengtsson K, Kristensen LE, Jacobsson LT. Drug adherence, response and predictors thereof for tocilizumab in patients with rheumatoid arthritis: results from the Swedish biologics register. Rheumatology (Oxford). 2015; 54(7):1186–93. Epub 2014/12/17. https://doi.org/10.1093/rheumatology/keu455 keu455 [pii]. PMID: 25505001.
35. Takahashi C, Kaneko Y, Okano Y, Taguchi H, Oshima H, Izumi K, et al. Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a 76-week prospective study. RMD Open. 2017; 3(1):e000363. Epub 2017/01/27. https://doi.org/10.1136/rmdopen-2016-000363 [pii]. PMID: 28123781; PubMed Central PMCID: PMC5237762.